Skip to main content
. 2026 Sep 28;17:1954344. doi: 10.3389/fimmu.2026.1954344

Figure 3.

Line chart titled “MG-ADL evolution” displays patient MG-ADL scores from October 2025 to March 2026, with scores fluctuating and periods of increase and decrease. Blue arrows indicate multiple regular intervals for efgartigimod dosing, annotated on the right.

Evolution of MG-ADL reported by patient via myMGverse app, ongoing use since October 2025. The blue arrows represent every efgartigimod dose (weekly dose for four weeks).